Trial Profile
Study to evaluate the effects of Monoamine Oxidase–B on [18F]THK5351 brain uptake using positron emission tomography and autoradiography of human brain
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Aug 2017
Price :
$35
*
At a glance
- Drugs Fluorine 18 THK 5351 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment; Progressive supranuclear palsy
- Focus Diagnostic use
- 29 Aug 2017 New trial record
- 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017
- 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017